ライフサイエンスコーパス: siRNA

1 siRNA knockdown of DPP6 antagonized the I(to) inhibition

2 siRNA knockdown or pharmacologic inhibition [GKT137831 (

3 siRNA potency was maintained when these modifications we

4 siRNA-induced knockdown of these receptors antagonized T

5 siRNA-mediated CRBN knock down in human endothelial cell

6 siRNA-mediated depletion of SNX1 in RPT cells from NT su

7 siRNA-mediated knockdown experiments indicated that ~78%

8 siRNA-mediated knockdown of striatal Rgs4 in DIO-suscept

9 siRNA-mediated STAT3 or GLI1 knockdown reduced promoter

10 siRNAs corresponding to integrated viral genes and LTR r

11 siRNAs corresponding to palindromic repeats are independ

12 siRNAs direct cleavage of target RNAs by guiding Argonau

13 e effect of HIF-2alpha knockdown; HIF-2alpha siRNA increasing osteoclast formation in 3D.

14 Moreover, the administration of anti-CTLA-4 siRNA-loaded NPs into CT26 and 4 T1 tumor -bearing mice

15 In this work, we conducted a siRNA screen to identify genes of the DNA damage respons

16 ith either p53 siRNA or acetylcholinesterase siRNA.

17 ibition, small interfering ribonucleic acid (siRNA) depletion, and antibody blocking.

18 of 21/22-nucleotide epigenetically activated siRNAs, which likely silence TEs via post-transcriptiona

19 focus on the pulmonary barriers that affect siRNA delivery, the disease-dependent pathological chang

20 by kinases, however, it negatively affected siRNA loading into human AGO2.

21 tiinflammatory agents, antiinfection agents, siRNA, and defatting agents.

22 dicate that NPSCs loaded with anti-TNF-alpha siRNA cause changes to the lipid composition in white pu

23 a human DUB cDNA library of 65 genes and an siRNA library of 98 genes, and identified USP20 as a deu

24 d live-cell fluorescent imaging to screen an siRNA library targeting genes involved in cellular traff

25 mall molecule inhibition of HSL activity and siRNA-mediated knock down of HSL abrogated LH-induced pr

26 Studies with a general Dynamin inhibitor and siRNA knockdown of DRP1 showed that DRP1 is required for

27 ocorticoid-induced macrophage migration, and siRNA-mediated knockdowns of GR and DPP4 blocked dexamet

28 RNAs and mRNAs from the gonads of piRNA and siRNA defective mutants to high-throughput sequencing.

29 ipt amounts via modulations of the piRNA and siRNA repertoires, with the clearest effects in somatic

30 CRISPR-mediated targeting and siRNA knockdown of ZNF263 in mammalian cell lines and hu

31 Enzyme inhibitor treatment and siRNA knockdown revealed that beta-secretase 1 (BACE1) i

32 FRbeta using a pharmacological inhibitor and siRNAs blocked TGFbeta-stimulated phosphorylation of pro

33 To identify the roles of piRNAs and siRNAs in regulating gene expression in Caenorhabditis e

34 a double-stranded RNA (dsRNA) transcript and siRNAs in transgenic plants.

35 conditioned medium from Corin-siRNA- or ANP-siRNA-transfected HK-2 cells was determined by western b

36 Similar effects were observed with ANP-siRNA transfection.

37 ere, we report a method to generate antibody-siRNA (1:2) conjugates (ARCs) that are structurally defi

38 Nox5 itself regulated VSMC phenotype as siRNA knockdown of Nox5 increased contractile marker exp

39 penetration for potential therapies such as siRNA to be evaluated with small quantities of human or

40 the synthesis of this dendrimer, as well as siRNA delivery to immune cells such as primary T and B c

41 including antisense oligonucleotides (ASOs), siRNAs, RNA-targeting clustered regularly interspaced sh

42 RNA-target genes, and 3730 repeat-associated siRNAs (mostly targeting Class I/Copia-Ivana- Copia-SIRE

43 gressive downregulation of repeat-associated siRNAs following genome merger and genome duplication in

44 r, intestine and kidney glomeruli of mice at siRNA doses that are at least tenfold lower than the siR

45 med on Shroom3 in mice using fullerene-based siRNA delivery, which demonstrated that Shroom3 knockdow

46 Inhalation-based siRNA delivery designed for efficient, targeted delivery

47 age Asxl2 expression, via nanoparticle-based siRNA delivery, prevented HFD-induced obesity.

48 d based on the results of antibody blockage, siRNA depletion of Mincle and its adaptor spleen tyrosin

49 ne induction was significantly attenuated by siRNA depletion of retinoic acid-inducible-I-like recept

50 -4 molecule on tumor-infiltrating T cells by siRNA-loaded chitosan-lactate (CL) nanoparticles to faci

51 exogenous Wnt ligands, which is inhibited by siRNA-mediated knockdown of Lef1.

52 Sortilin inhibition by siRNA and the pharmacologic inhibitor AF38469 strongly r

53 Likewise, reduction of macroH2A by siRNA interference mimicks transcriptional reactivation.

54 plant cell cultures are stably maintained by siRNA and H3K9me2 independent of the canonical RNA-direc

55 omics screen for phosphotargets modulated by siRNA-mediated depletion of CIP2A, PME-1, and SET (to re

56 B protein, by spironolactone treatment or by siRNA transfection, inhibits SM-dependent late lytic gen

57 by chemical inhibitors of MET or c-Src or by siRNA-mediated knockdown of MET.

58 on of mTOR, unless RHA was down-regulated by siRNA.

59 nduced [Ca(2+)](i) increase were reversed by siRNA for the RvE1 receptor, and the actions of RvD1 wer

60 meiotic spindle, and microinjection of Cdc23 siRNA caused decreased ratios of metaphase-to-anaphase t

61 Production of specific CgCOM1 siRNA in transgenic chilli and tomato RNAi lines was con

62 Impressively, chemosynthetic siRNAs against VAL shows great therapeutic potential in

63 The chemical structure of conjugated siRNA may significantly impact invivo efficacy, particul

64 nt N-acetylgalactosamine (GalNAc)-conjugated siRNAs is the remarkable durability of silencing that ca

65 Conversely, siRNA-mediated BAG6 knockdown prevented chronic MPP(+) s

66 s treated with conditioned medium from Corin-siRNA- or ANP-siRNA-transfected HK-2 cells was determine

67 nd their captured regions and 24nt crosstalk siRNAs were linked with CHH methylation.

68 Intranasal delivery of CXCL10 siRNA blocked Th1 infiltration but did not fully rescue

69 utations in components of the RDR6-SGS3-DCL4 siRNA system and the flavonoid pathway reveals genetic/e

70 mphiphilic dendrimer that is able to deliver siRNA to a variety of cells, including primary immune ce

71 ion presents a unique opportunity to deliver siRNA to the target organ during ex situ preservation.

72 Several strategies have been used to deliver siRNA, and pretransplant machine perfusion presents a un

73 e, safe and non-invasive means of delivering siRNA to the cornea.

74 NA recognition and mutator complex-dependent siRNA amplification, respectively.

75 Conversely, dsRNA-derived siRNA populations (mainly 21- and 22-nt) were detected i

76 As in Arabidopsis, all TE-derived siRNAs were depleted in Capsella nrpd1 microspores.

77 es the profile of mutations in virus-derived siRNAs for three members of the family Potyviridae: Turn

78 iRNAs) derived from viral RNA (virus-derived siRNAs) through gene silencing.

79 the generation of mutations in virus-derived siRNAs.

80 th two sources of mutations in virus-derived siRNAs: viral RNA-dependent RNA polymerases responsible

81 dcl3 and dcl4 to the msh1 rootstock disrupts siRNA production and reveals RdDM targets of methylation

82 methylation inhibitors (Azacytidine or Dnmt1-siRNA), prevented Mfn2 and Mlh1 hypermethylation, and am

83 Most often, 24-nt-dominated siRNA loci occurred in intergenic regions, especially at

84 In contrast, 21-nt-dominated siRNA loci were most often derived from double-stranded

85 lls transfected with either control or eIF3e siRNAs.

86 Here, we outline the emerging siRNA design principles and discuss the consequences for

87 In mice, nanoparticles encapsulating siRNA sequences targeting the proteins stromal-derived f

88 This establishes a role for endo siRNAs in the aging process and identifies downstream ge

89 cal processes that are regulated by the endo siRNAs to affect longevity.

90 Furthermore, we identify an endo-siRNA-regulated tyrosine phosphatase, which limits the l

91 S2 cells that synthetic repeat-derived endo-siRNA mimics are sufficient to rescue Dcr-2-deficiency-i

92 ver, in contrast to miRNAs, the role of endo-siRNAs in aging remains unexplored.

93 1 mutants fail to produce the secondary endo-siRNAs required for the silencing of piRNA targets.

94 As are also known to give rise to small endo-siRNAs to help maintain heterochromatin at their sites o

95 Altogether, our findings point to endo-siRNAs as a link between germline removal and the HSF-1

96 captured fragments were older, mapped fewer siRNAs, and were slightly less methylated than TEs witho

97 4Bb the Gapdh panels for Fhit siRNA were incorrect and have been replaced with scans f

98 Similarly, following siRNA-mediated knockdown of ODC1, UC cells undergo doubl

99 Attempts to use antibodies for siRNA delivery have been reported but these strategies u

100 principles and discuss the consequences for siRNA disposition and biotransformation.

101 We propose a conceptual framework for siRNA ADME evaluation, contextualizing the site of biotr

102 reatment regimen that would be necessary for siRNA-induced gene silencing.

103 Of note, results from siRNA-mediated knockdown of activating transcription fac

104 to bind nucleic acid and deliver functional siRNA to corneal cells both in vitro and in vivo.

105 old et al. demonstrated the first functional siRNA delivery by diphtheria toxin (DT) in vitro, markin

106 We show that functional siRNA can be liberated from these compartments and loade

107 Further, siRNA-mediated depletion of TAK1 or RELA resulted in RPL

108 efficacy of molecular constructs to generate siRNAs against specific gene targets.

109 drugs to the tumor sites, delivery of genes (siRNA,pDNA) and co-delivery of drugs and genes to combat

110 locked by the GR antagonist RU-486 and by GR siRNA transfection and that DPP4 enzyme activity is redu

111 Anti-HBV siRNAs and therapeutic vaccines are each being tested in

112 s, treatment with PCI34051 or specific HDAC8 siRNA was also effective in inhibiting transforming grow

113 ed with commercial platforms carrying higher siRNA doses (6.25 nM).

114 nd high correlation with a previous in-house siRNA effector node (siREN) study and external studies.

115 However, siRNA is a molecule that is highly susceptible to enzyma

116 possess measurable TRPM7 currents; however, siRNA knockdown did not directly affect action potential

117 Importantly, siRNA-induced deficiency of CNN3 in lens epithelial cell

118 In siRNA gene knockdown experiments, silencing GP-5, GRN, a

119 than conventional SNAs without a decrease in siRNA activity.

120 e companion vegetative nucleus, resulting in siRNA production and the intercellular movement of these

121 Mutations in siRNAs derived from a PRSV coat protein transgene in the

122 Here, using several approaches, including siRNA-mediated gene silencing, confocal microscopy, and

123 res for transgene-free and force-independent siRNA delivery and gene silencing in mature plants.

124 Individual siRNA sequences of all types showed very little conserva

125 Finally, in vivo delivery of the ITCH siRNA using nanoparticles to the neuroblastoma xenograft

126 Transfection of these cell lines with ITCH siRNA could effectively silence the ITCH expression, and

127 Downregulation of LncRNA MALAT1 by its siRNA prevented glucose-induced increase in Keap1 and fa

128 dual-luciferase-based, genome-wide E3 ligase siRNA library screen and identified ASB13 as an E3 ubiqu

129 using several human lung cancer cell lines, siRNA-mediated gene silencing, immunoblotting, quantitat

130 This dendrimer-mediated siRNA delivery largely outperforms the standard electrop

131 source and cell type; the dendrimer-mediated siRNA delivery; and subsequent functional assays, which

132 promote the second pollen mitosis, mediates siRNA movement to reinforce heterochromatic silencing in

133 However, the manner in which modified siRNA duplex strands that comprise the SNA lead to gene

134 esults demonstrate that 2'-5'/3'-5'-modified siRNAs, when properly designed, can offer an efficient n

135 epigenetic conflict, donor genes mapped more siRNAs and were more methylated than genes with no evide

136 Moreover, siRNA complexed with this silicon-based hybrid and appli

137 ly polymerases were validated using multiple siRNAs in a panel of NSCLC and colorectal cancer cell li

138 omputational tools for classification of nat-siRNAs are limited in number and can be computationally

139 s allowing for comprehensive analysis of nat-siRNAs in larger and more complex organisms for the firs

140 ication of the function of the predicted nat-siRNAs.

141 anscript-derived small interfering RNAs (nat-siRNAs) are a class of functional small RNA (sRNA) that

142 y identifying tissue and stress specific nat-siRNAs in multiple Arabidopsis thaliana datasets.

143 s penetration of a candidate neuroprotective siRNA.

144 independent, with neither BFA treatment nor siRNA-mediated ARF1 knockdown affecting HAZV gene expres

145 tor, NS1619, rescued BK(G354S) cells but not siRNA-treated cells, by selectively blocking the mutant

146 Notably, siRNA knockdown of both p53 and PTEN activated MEOX1 exp

147 nuated by mellitin (Nox5 inhibitor) and Nox5 siRNA, while p53 phosphorylation was inhibited by NoxA1d

148 Most 24-nt siRNAs are dependent on RNA Pol IV and RNA-DEPENDENT RNA

149 chromatic regions, while in egg cells, 24-nt siRNAs were concentrated at a smaller number of heteroch

150 In sperm cells, 24-nt siRNAs were spread across heterochromatic regions, while

151 We found that 24-nt siRNAs, which are a hallmark of RNA-directed DNA methyla

152 i produced mainly 24- and 21-nucleotide (nt) siRNAs, respectively.

153 In vivo application of siRNA formulation to SKH-1E hairless mice significantly

154 The two most numerous classes of siRNA loci produced mainly 24- and 21-nucleotide (nt) si

155 rn1p, including affecting the composition of siRNA species in the cell, influencing the efficiency of

156 ation of these nucleotides in the context of siRNA.

157 Delivery of siRNA against vascular endothelial growth factor (siVEGF

158 Efficient delivery of siRNA directly to the lung, however, is relatively compl

159 e platform for effective topical delivery of siRNA for treating genetic skin diseases.

160 Topical delivery of siRNA is an attractive alternative option to mediate RNA

161 Herein, we describe topical delivery of siRNA using ionic liquids (ILs) capable of complexing wi

162 Delivery of siRNA-peptide nanoplexes co-targeting MK2 and XPA to pre

163 sed delivery platform for ocular delivery of siRNA.

164 The high doses of siRNA and delivery vehicle that are thus required to ach

165 s in the cell, influencing the efficiency of siRNA loading into Argonaute, degradation of cleaved pas

166 ully define efficacy, and that the impact of siRNA chemical structure on activity is driven by intrac

167 Furthermore, infusion of siRNA targeting MORs specifically in mPOA both suppresse

168 Injections of siRNA into skin, though effective, are painful and cover

169 Here, we show that the integration of siRNA sequences into a Dicer-independent RNA stem-loop b

170 Consequently, thorough investigations of siRNA absorption, distribution, metabolism, and excretio

171 By means of siRNA-mediated transfection and electron microscopy we s

172 cond pollen mitosis but also the movement of siRNA from the vegetative nucleus to the male germline,

173 NPs encapsulate a high weight percentage of siRNA while also carrying a synthetic biosensing peptide

174 he epidermis impedes effective permeation of siRNA into the skin.

175 lative to vegetative tissues, reminiscent of siRNA patterns in DDM1-type nucleosome remodeler mutants

176 In terms of siRNA loading capacity, system versatility, and potency

177 We show that piRNAs and an abundant class of siRNAs known as WAGO-class 22G-RNAs are required for pro

178 esigned, can offer an efficient new class of siRNAs with diminished immune-stimulatory responses.

179 nown as RNAi, which involves the delivery of siRNAs that downregulate endogenous genes to confer resi

180 r that were given subcutaneous injections of siRNAs had reduced levels of HBV antigens, HBV replicati

181 The designed pool of siRNAs can be used to construct a long double-strand RNA

182 igins of regiospecific changes in potency of siRNAs and the increased protection against 5'-exonuclea

183 We report on the synthesis of siRNAs containing both 2'-5'- and 3'-5'-internucleotide

184 that a new era has dawned in oligonucleotide/siRNA clinical therapeutics.

185 nternucleotide linkages and their effects on siRNA structure, function, and interaction with RNAi pro

186 heir role in pulmonary disease and impact on siRNA delivery, as well as the recent development on the

187 rated its utility in multiple CRISPR/CAS9 or siRNA HTS studies.

188 Genetic deletion (ICAM-1 knockout mice) or siRNA-mediated knockdown of ICAM-1 in isolated murine an

189 Expression of mutant MxB or siRNA knockdown of MxB leads to fragmented mitochondria

190 by dichloroacetate (in RVfib and in vivo) or siRNA targeting PDK 1 and 3 (in RVfib).

191 nt of A549 cells transfected with either p53 siRNA or acetylcholinesterase siRNA.

192 racellular vesicles that efficiently package siRNA can significantly reduce its therapeutic dose.

193 e PAT1-ZBP1 interaction in neurons with PAT1 siRNA or a dominant-negative ZBP1 construct diminished l

194 Importantly, administration of Pdcd4 siRNA or an interfering peptide that interrupts the Pdcd

195 nly a small minority of the total sRNA pool; siRNA locus annotations have lagged far behind.

196 Cept1 endoribonuclease-prepared siRNA decreased PPARalpha phosphorylation in ECs, which

197 In contrast, loci that fail to produce siRNA may be targeted for demethylation when the cell cy

198 nome, especially at loci which also produced siRNAs in other tissues.

199 expressed response regulator, which produces siRNAs that block this gene's expression, repressing fem

200 rmed homogeneous sizes of ~200 nm, protected siRNA from degradation, and showed excellent biocompatib

201 uding binding analysis with fusion proteins, siRNA-mediated gene silencing, RT-PCR, and knockout mice

202 ocuses on the barriers that impact pulmonary siRNA delivery and successful recent approaches to advan

203 l as the recent development on the pulmonary siRNA delivery systems.

204 For both mi- and ra-siRNAs, we detected differential expression patterns fol

205 We show that Rab7a siRNA inhibition enhances IGF-1 and HGF signalling in be

206 ch position on the strand, and the resulting siRNAs were evaluated for their ability to inhibit Ttr m

207 lement (MITE)-derived small interfering RNA (siRNA) (here referred to as siR109944) expression was cl

208 l inhibitor GW4869 or small interfering RNA (siRNA) against SMPD3 results in defects in the TNF-alpha

209 We demonstrated using small interfering RNA (siRNA) depletion and inhibitor studies that KSHV vIL-6 c

210 eic Acid (ANA) within small interfering RNA (siRNA) duplexes that were otherwise fully modified with

211 en made with modified small interfering RNA (siRNA) duplexes, SNAs act as single-entity transfection

212 Small interfering RNA (siRNA) knockdown of endogenous BK channels had similar e

213 subunit of mTORC1, by small interfering RNA (siRNA) negatively affects ZIKV protein expression and vi

214 in gonads, while the small interfering RNA (siRNA) pathway is dedicated to TE somatic control and de

215 rformed a large-scale small interfering RNA (siRNA) screen targeting host kinases that regulated MuV

216 sized that a suitable small interfering RNA (siRNA) targeting hepatic FXIII-B could safely decrease F

217 ere, we propose using small interfering RNA (siRNA) therapeutics to directly target the undruggable K

218 th cells treated with small interfering RNA (siRNA) to Rab5 or Rab7 and cells expressing dominant neg

219 emical inhibitors and small interfering RNA (siRNA) were used to confirm the role of TLR3.

220 rticles encapsulating small interfering RNA (siRNA), for the silencing of genes in bone-marrow endoth

221 tilized; IRF5 or IRF4 small interfering RNA (siRNA), lentivirus, and conditional knockout (CKO) techn

222 cess was disrupted by small interfering RNA (siRNA)-based down-regulation of an actin regulator, by p

223 RNA (sgRNA)/dCas9 and small interfering RNA (siRNA)-mediated protein knockdown, combined with an imag

224 -specific genes using small interfering RNA (siRNA).

225 stemic trafficking of small interfering RNA (siRNA)/microRNA (miRNA) is a central component in this r

226 We speculate that this pUG RNA-siRNA silencing loop enables parents to inoculate progen

227 ug development, with small interfering RNAs (siRNA) and microRNAs gaining traction in the therapeutic

228 on, as well as 24-nt small interfering RNAs (siRNAs) and histone H3 lysine dimethylation (H3K9me2), w

229 t enhance potency of small interfering RNAs (siRNAs) and that reduce off-target effects, immune stimu

230 ng RNAs (piRNAs) and small interfering RNAs (siRNAs) are distinct classes of small RNAs required for

231 Small interfering RNAs (siRNAs) derived from RNAi-5x were significantly more abu

232 ate 21-24 nucleotide small interfering RNAs (siRNAs) derived from viral RNA (virus-derived siRNAs) th

233 Small interfering RNAs (siRNAs) have revolutionized the treatment of liver disea

234 3 into 24-nucleotide small interfering RNAs (siRNAs) that guide RNA-directed DNA methylation.

235 down circ-MDM2 with small interfering RNAs (siRNAs) that targeted circ-MDM2 did not alter MDM2 mRNA

236 croRNAs (miRNAs) and small interfering RNAs (siRNAs).

237 RNAs) and endogenous short interfering RNAs (siRNAs).

238 plates to synthesize small interfering RNAs (siRNAs).

239 However, robust siRNA delivery to other tissues represents a major techn

240 F-alpha, whereas NPSCs loaded with scrambled siRNA do not cause the predicted changes.

241 /2, effects recapitulated in Cav-1 silenced (siRNA) VSMCs.

242 cation (CC1-KO->WT), whereas ASK1 silencing (siRNA) promoted cytoprotection in cold-stressed and dama

243 al sporophytic tissues is required for siren siRNA accumulation.

244 In the endosperm, siren siRNAs show a marked maternal bias, and siren expression

245 ted with a miR-133b mimic or with a specific siRNA targeting FoxO1 recapitulates the metabolic effect

246 Silencing NOX1 using NOX1-specific siRNA mitigated radiation-induced oxidative stress and c

247 RNAi-5x-specific siRNAs were significantly, three to fivefold, more abund

248 S1842856 or transfection with FOXO1-specific siRNAs protected against DOX-induced apoptosis and mitoc

249 e given either entecavir or non-HBV-specific siRNAs and vaccine components.

250 antibody, and utilizes chemically stabilized siRNA.

251 In mammalian systems siRNA-mediated knockdown of SKI genes inhibited replicat

252 Tailoring siRNAs to silence genes vital for cancer cell growth and

253 U145 proliferation compared to non-targeting siRNA, which was in the same direction as the original s

254 le PT cell lines treated with OCRL-targeting siRNA, and in orcl-mutant zebrafish.

255 particles (NPs) which deliver Rac1-targeting siRNA together with cisplatin and effectively reverses N

256 When the host silences these TEs, siRNAs homologous to the captured regions may also targe

257 within the mosquito salivary gland and that siRNA mediated knockdown of AeOBP22 led to reduced mosqu

258 in vitro by histone ubiquitylation, and that siRNA-mediated depletion of HECTD1 leads to deficiencies

259 We demonstrate that siRNA-mediated knockdown of ODC1 expression elicits geno

260 We found that siRNA accumulation and stability in acidic intracellular

261 We found that siRNA depletion of ITGB3 in vIL-6-expressing endothelial

262 We observed that siRNA-mediated knockdown of TRIM28 and TRIM27 inhibited

263 ast cancer cell culture models revealed that siRNA-mediated silencing of TMPRSS13 expression decrease

264 Our findings suggest that siRNA tissue accumulation does not fully define efficacy

265 The siRNA with ANA at position 7 in the seed region was acti

266 tic machine-learning approach to analyze the siRNA-based screening data.

267 the expression of the genes targeted by the siRNA in the liver, intestine and kidney glomeruli of mi

268 Furthermore, the siRNA studies showed that loss of PACS-1 expression was

269 minimally affected 5'-phosphorylation of the siRNA by kinases, however, it negatively affected siRNA

270 ses that are at least tenfold lower than the siRNA doses typically delivered via lipid nanoparticles.

271 l at the 5' end of the antisense strand, the siRNAs with ANA at position 6 or 7 in the seed region ha

272 Screening of these siRNAs against their corresponding mRNA targets showed t

273 tion and the intercellular movement of these siRNAs to reinforce TE silencing in sperm.

274 gating lipids (e.g. docosanoic acid, DCA) to siRNA supports extrahepatic delivery, but tissue accumul

275 ne silencing (VIGS) or synthetic transacting siRNA vectors for gene silencing.

276 Fine-tuning siRNA chemical structure for optimal extrahepatic effica

277 atory tool and therapeutic reality, with two siRNA drugs now clinically approved, this modality has f

278 ese effects were the same with either of two siRNAs.

279 regulated gene expression was observed upon siRNA-mediated IKBKE depletion or pharmacological inhibi

280 Using siRNA- or shRNA-mediated knockdown, we demonstrate that,

281 al binding partner, ARNT were depleted using siRNA to determine their role in activating expression o

282 This was done using siRNA (siCas-3) conjugated to magnetic nanoparticles (MN

283 COP1 knockdown using siRNA prevents degradation of c-Jun, ETV4, and ETV5 in c

284 cally inhibiting expression of FLIP(L) using siRNA or entinostat (a clinically relevant class-I HDAC

285 the role of RPS6KB1 in regulating MuV using siRNA knockdown, an inhibitor, and RPS6KB1 knockout cell

286 Knockdown of TLR3 using siRNA decreased the poly I:C-induced expression of these

287 ized regulators, elements and variants using siRNA knockdowns, CRISPR-based editing, and luciferase a

288 Using siRNAs to genetically manipulate immune cells is importa

289 Using siRNAs, we observe that all 26 candidates tested induce

290 AnxA8 suppression in RPE cells via siRNA or administration of FR induced neuronal-like cell

291 ia and screened both a druggable genome-wide siRNA library and a small neuroactive compound library.

292 e transiently transfected diploid cells with siRNA against ESPL1/Separase, a protease responsible for

293 ction of human corneal epithelial cells with siRNA-ProSilic(R) formulation was followed by a successf

294 ce was assessed by treating DLD-1 cells with siRNA-SMPD1.

295 nic liquids (ILs) capable of complexing with siRNA non-covalently and delivering it effectively.

296 31 breast cancer cell lines constructed with siRNA and CRISPR/Cas9 technologies to vary only in NAT1

297 istently, silencing of HDAC3 expression with siRNA largely recapitulated the effects of HDAC3/6i on m

298 inhibitors, GW280264X and GI254023X, or with siRNA significantly reduced basal and TNFalpha-induced c

299 nd, likewise, in vitro experiments with XBP1 siRNA.

300 The aura of their younger siRNA relatives had also faded during the past 15 years.